Association between post-operative hPG
biomarker
glioblastoma
hPG(80)
prognostic
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
10
02
2023
revised:
06
07
2023
accepted:
02
08
2023
medline:
30
10
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG Circulating hPG
Sections du résumé
BACKGROUND
Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG
PATIENTS AND METHODS
A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG
RESULTS
Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG
CONCLUSIONS
Circulating hPG
Identifiants
pubmed: 37713930
pii: S2059-7029(23)00861-X
doi: 10.1016/j.esmoop.2023.101626
pmc: PMC10594012
pii:
doi:
Substances chimiques
big gastrin
3BL184GALN
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101626Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Clin Cancer Res. 2017 Sep 1;23(17):5267-5280
pubmed: 28600477
J Clin Invest. 2000 Aug;106(4):533-9
pubmed: 10953028
Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1097-110
pubmed: 12881229
Cancers (Basel). 2021 Jan 20;13(3):
pubmed: 33498444
Neurooncol Adv. 2022 Nov 11;4(Suppl 2):ii45-ii52
pubmed: 36380859
Int J Clin Exp Med. 2015 Jan 15;8(1):456-63
pubmed: 25785017
Anal Methods. 2021 Oct 8;13(38):4468-4477
pubmed: 34494619
Oncogene. 2015 Jun 11;34(24):3120-30
pubmed: 25109333
Regul Pept. 2006 Jan 15;133(1-3):47-53
pubmed: 16213037
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445128
J Neurooncol. 2020 Sep;149(3):391-400
pubmed: 32915353
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2016 Jun 15;76(12):3618-28
pubmed: 27197176
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurooncol Adv. 2022 Nov 11;4(Suppl 2):ii41-ii44
pubmed: 36380864
Biochem J. 2008 Oct 1;415(1):35-43
pubmed: 18554181
Cancers (Basel). 2022 Jan 13;14(2):
pubmed: 35053564
EBioMedicine. 2020 Jan;51:102574
pubmed: 31877416
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Gut. 2001 Jan;48(1):47-52
pubmed: 11115822
Cancer Res. 1996 Sep 15;56(18):4111-5
pubmed: 8797575